|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuronal death in Parkinson's disease (PD), one of the most common neurodegenerative disorders in the adult and aging population is probably caused by misfolding of synaptic proteins such as alpha-synuclein.
|
12428718 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
alpha-Synuclein has been implicated in the pathogenesis of Parkinson disease (PD) and related neurodegenerative disorders.
|
12239163 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Accumulation of alpha-synuclein has been associated with neurodegenerative disorders, such as Lewy body disease and multiple system atrophy.
|
12111846 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Specific questions related to patterns of protein expression (e.g. tau, Abeta, alpha-synuclein) in multiple regions of large numbers of brain specimens (from patients with neurodegenerative diseases) can be efficiently examined using TMA technology.
|
12152780 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The mice expressing the A53T human alpha-Syn, but not wild-type or the A30P variants, develop adult-onset neurodegenerative disease with a progressive motoric dysfunction leading to death.
|
12084935 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The mice expressing the A53T human alpha-Syn, but not wild-type or the A30P variants, develop adult-onset neurodegenerative disease with a progressive motoric dysfunction leading to death.
|
12084935 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, treatments that block the accumulation of A beta and alpha-synuclein might benefit a broad spectrum of neurodegenerative disorders.
|
12223532 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders.
|
11813001 |
2002 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
|
12814657 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In recent years, it has become increasingly clear that many neurodegenerative diseases involve aggregation and deposition of misfolded proteins such as amyloid beta, tau, alpha-synuclein and polyglutamine containing proteins.
|
12605877 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
LHGDN |
Alpha-synuclein (alpha-syn) and tau polymerize into amyloid fibrils and form intraneuronal filamentous inclusions characteristic of neurodegenerative diseases.
|
12714745 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, the deposition of alpha-synuclein, an abundant presynaptic brain protein, as fibrillary aggregates in affected neurons or glial cells,was highlighted as a hallmark lesion of a subset of neurodegenerative disorders, including PD, DLB and multiple system atrophy collectively referred to as synucleinopathies.
|
14579119 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, (1) a frontal lobe syndrome-like personality change may be one of the characteristic clinical features of early-onset CWP-AD, (2) the deposition pattern of Abeta40 and Abeta42 in CWP-AD is more variable than that of presenilin-1-linked cases, (3) Abeta deposition can result in development of dementia without tau pathology, and (4) CWP-AD with LBs and several other neurodegenerative disorders with LBs share a common process involving alpha-synuclein and NAC deposition.
|
12883830 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this article, we review the progress of studies on alpha-synuclein and its role in alpha-synuclein-related neurodegenerative diseases.
|
12719631 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein: its biological function and role in neurodegenerative diseases.
|
12794302 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
alpha-Synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, are neurodegenerative disorders in which abnormal inclusions containing alpha-synuclein accumulate in selectively vulnerable neurons and glia.
|
12819014 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Microglial activation in these neurodegenerative disorders suggests that neuroinflammatory responses might interact with alpha-synuclein and contribute to the pathogenesis of these disorders.
|
12868067 |
2003 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Cytoplasmic deposition of alpha-synuclein aggregates is a common pathological feature of many neurodegenerative diseases.
|
14985429 |
2004 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neurodegenerative diseases classified as synucleinopathies are characterized by alpha-synuclein inclusions.
|
15581183 |
2004 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The comparison of these characteristics with that of alpha-synuclein and tau, involved also in neurodegenerative diseases, suggested that although the primary sequences of these proteins are entirely different, there are similarities in their well-defined unstructured segments interrupted by "stabilization centres", phosphorylation and tubulin binding motives.
|
15567525 |
2004 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in the alpha-synuclein (alpha-syn) gene are responsible for a rare familial parkinsonism syndrome, a finding that has led to extensive characterization of altered alpha-syn structure in sporadic Parkinson's disease (PD) and other neurodegenerative disorders.
|
15144854 |
2004 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The presynaptic protein alpha-synuclein has been implicated in both neuronal plasticity and neurodegenerative disease, but its normal function remains unclear.
|
15033366 |
2004 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, aberrant accumulation of alpha- and beta-synuclein in degradative organelles are novel features of PS1 -/- neurons, and similar events may promote the formation of alpha-synuclein inclusions associated with neurodegenerative diseases.
|
15123735 |
2004 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
LHGDN |
We suggest that p25alpha plays a pro-aggregatory role in the common neurodegenerative disorders hall-marked by alpha-synuclein aggregates.
|
15590652 |
2005 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-synuclein is a major component of several pathological lesions diagnostic of specific neurodegenerative disease such as Parkinson's disease.
|
16081040 |
2005 |